Delivery Order SPE2DB25D7068-SPE2DB25FTXYS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,661.77 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a firm fixed-price, non-set-aside competitive award. The place of performance is listed as Conshohocken, Pennsylvania, which is the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.96 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL quantities. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a $44,381.09 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion targeted for August 12, 2025. This competitive, non-set-aside award reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,168.32 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $11,725.57 and an ultimate completion date of August 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order valued at $17,745.69 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The contract, issued on September 4, 2025, with a completion date of September 5, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work from its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml quantities, valued at $2,424.16. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and carries no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $9,988.86 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials. This firm fixed-price, competitively awarded contract is classified as a delivery order with an ultimate completion date of July 25, 2025, and requires performance at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating AmerisourceBergen competed against other...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) pharmaceutical product, with a contract ceiling value of $1,253.36. The award, issued on July 31, 2025, carries a firm fixed price structure with an ultimate completion date of August 1, 2025. This non-competitive, non-set-aside delivery order represents part of AmerisourceBergen's ongoing support of federal medical supply chains, with performance fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $3,869.24 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical...
- SPE2DB25D7068Indefinite Delivery Contract
- SPE2DB25D7068-SPE2DB25FTXYSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,879.98 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) injectable medication. This contract is a firm fixed price delivery order with an ultimate completion date of September 15, 2025, and was awarded on September 12, 2025. The award carries no set-aside designation, indicating it was competitively awarded. Performance will be completed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters is located. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The Ozempic delivery supports the Defense Health Agency and other federal healthcare systems' ongoing pharmaceutical needs and demonstrates the company's role as a critical vendor within the Department of Defense's medical supply chain for both brand-name and specialty medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/12/25 |